Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Durante

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Hemasphere|April 20, 2026
Whole-genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myelomaChrissy Baker, Elizabeth Hill, Dickran Kazandjian, et al.
The New England Journal of Medicine|October 28, 2020
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19Peter Chen, Ajay Nirula, Barry Heller, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Hemasphere|September 25, 2025
Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myelomaJuan-Jose Garces, Benjamin Diamond, Tereza Sevcikova, et al.
JAMA|January 21, 2021
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical TrialRobert L Gottlieb, Ajay Nirula, Peter Chen, et al.
Nature Medicine|August 31, 2023
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myelomaHolly Lee, Sungwoo Ahn, Ranjan Maity, et al.
The New England Journal of Medicine|July 14, 2021
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19Michael Dougan, Ajay Nirula, Masoud Azizad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Genomic Classification and Individualized Prognosis in Multiple MyelomaFrancesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2025
Genomics Define Malignant Transformation in Myeloma Precursor ConditionsFrancesco Maura, P Leif Bergsagel, Bachisio Ziccheddu, et al.
Biorxiv : the Preprint Server for Biology|December 19, 2025
Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myelomaFrancesco Maura, Ciara L Freeman, Kylee H Maclachlan, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Hemasphere|April 20, 2026
Whole-genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myelomaChrissy Baker, Elizabeth Hill, Dickran Kazandjian, et al.
The New England Journal of Medicine|October 28, 2020
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19Peter Chen, Ajay Nirula, Barry Heller, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Hemasphere|September 25, 2025
Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myelomaJuan-Jose Garces, Benjamin Diamond, Tereza Sevcikova, et al.
JAMA|January 21, 2021
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical TrialRobert L Gottlieb, Ajay Nirula, Peter Chen, et al.
Nature Medicine|August 31, 2023
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myelomaHolly Lee, Sungwoo Ahn, Ranjan Maity, et al.
The New England Journal of Medicine|July 14, 2021
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19Michael Dougan, Ajay Nirula, Masoud Azizad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Genomic Classification and Individualized Prognosis in Multiple MyelomaFrancesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2025
Genomics Define Malignant Transformation in Myeloma Precursor ConditionsFrancesco Maura, P Leif Bergsagel, Bachisio Ziccheddu, et al.
Biorxiv : the Preprint Server for Biology|December 19, 2025
Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myelomaFrancesco Maura, Ciara L Freeman, Kylee H Maclachlan, et al.
Pageof 2